Sakar Healthcare Limited — Ceftriaxone Exporter Profile
Indian Pharmaceutical Exporter · #7 for Ceftriaxone · $4.2M export value · DGFT Verified
Sakar Healthcare Limited is the #7 Indian exporter of Ceftriaxone with $4.2M in export value and 83 verified shipments. Sakar Healthcare Limited holds a 1.5% market share in Ceftriaxone exports across 16 countries. The company exports 6 pharmaceutical products worth $16.0M across 4 therapeutic categories.
Sakar Healthcare Limited — Ceftriaxone Export Profile: Buyers & Destinations
Where Does Sakar Healthcare Limited Export Ceftriaxone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| ETHIOPIA | $863.7K | 21 | 42.5% |
| MOZAMBIQUE | $254.0K | 9 | 12.5% |
| KENYA | $163.7K | 13 | 8.1% |
| ALBANIA | $144.5K | 3 | 7.1% |
| CONGO, THE DEMOCRATIC REPUBLIC OF THE | $131.1K | 3 | 6.5% |
| FRANCE | $104.7K | 7 | 5.2% |
| ZIMBABWE | $99.1K | 3 | 4.9% |
| CAMEROON | $74.3K | 4 | 3.7% |
| YEMEN, DEMOCRATIC | $42.7K | 1 | 2.1% |
| GUINEA | $35.0K | 1 | 1.7% |
Sakar Healthcare Limited exports Ceftriaxone to 16 countries. The largest destination is ETHIOPIA accounting for 42.5% of Sakar Healthcare Limited's Ceftriaxone shipments, followed by MOZAMBIQUE (12.5%) and KENYA (8.1%). These destinations reflect Sakar Healthcare Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ceftriaxone from Sakar Healthcare Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| M/S PHARMACEUTICAL AND CHEMICAL DIS | MOZAMBIQUE | $200.3K | 7 |
| TO THE ORDER | ETHIOPIA | $138.0K | 4 |
| TO THE ORDER OF AWASH BANK S.C | ETHIOPIA | $134.0K | 4 |
| M/S. PRINCE PHARMA DEPOT PHARMACETI | CONGO, THE DEMOCRATIC REPUBLIC OF THE | $131.1K | 3 |
| PLANET PHARMA | FRANCE | $104.7K | 7 |
| TO THE ORDER OF ZEMEN BANK S.C. | ETHIOPIA | $100.0K | 2 |
| TO THE ORDER OF ZAMZAM BANK | ETHIOPIA | $100.0K | 2 |
| M/S. PHARMA-ROC S.A.R.L. REPARTITEU | CAMEROON | $74.3K | 4 |
| AAFIYA AFRICA LIMITED | KENYA | $71.0K | 2 |
| SODIPHARM | GUINEA BISSAU | $68.6K | 2 |
Sakar Healthcare Limited supplies Ceftriaxone to 38 buyers globally. The largest buyer is M/S PHARMACEUTICAL AND CHEMICAL DIS (MOZAMBIQUE), followed by TO THE ORDER (ETHIOPIA) and TO THE ORDER OF AWASH BANK S.C (ETHIOPIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ceftriaxone Export Value and How Much Does Sakar Healthcare Limited Contribute?
India exported $98.3M worth of Ceftriaxone through 11,257 shipments from 850 suppliers to 162 countries, serving 2,555 buyers globally. Sakar Healthcare Limited contributes $4.2M to this total, accounting for 1.5% of India's Ceftriaxone exports. Sakar Healthcare Limited ships Ceftriaxone to 16 countries through 38 buyers.
What Is the Average Shipment Value for Sakar Healthcare Limited's Ceftriaxone Exports?
Sakar Healthcare Limited's average Ceftriaxone shipment value is $50.0K per consignment, based on 83 shipments totaling $4.2M. The largest destination is ETHIOPIA (42.5% of Sakar Healthcare Limited's Ceftriaxone exports).
How Does Sakar Healthcare Limited Compare to Other Indian Ceftriaxone Exporters?
Sakar Healthcare Limited ranks #7 among 850 Indian Ceftriaxone exporters with a 1.5% market share. The top 3 exporters are INNOVA CAPTAB LIMITED ($30.0M), AUROBINDO PHARMA LTD ($9.2M), CIPLA LIMITED ($6.7M). Sakar Healthcare Limited processed 83 shipments to 16 destination countries.
What Ceftriaxone Formulations Does Sakar Healthcare Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| COMBIPACK OF CEFTRIAXONE SODIUM AND TAZO | $131.1K | 3 |
| CEFTRIAXONE FOR INJECTION USP & STERILIS | $129.8K | 4 |
| CEFTRIAXONE FOR INJECTION USP 1000MG (SEFIXI 1000) (AS PER INVOICE) | $100.0K | 2 |
| SEFIXI-1000 ( CEFTRIAXONE FOR INJECTIONUSP 1000MG ) (AS PER INVOICE) | $100.0K | 2 |
| CEFTRIAXONE FOR INJECTION USP (SEFIXI 1000 ) (AS PER INVOICE) | $100.0K | 2 |
| SEFIXI 1000 CEFTRIAXONE FOR INJECTIONUSP 1000MG AS PER INVOICE | $100.0K | 2 |
| SEFIXI 1000 - (CEFTRIAXONE FOR INJECTIONUSP 1000MG) (AS PER INVOICE) | $98.1K | 2 |
| CEFTRIAXONE FOR INJECTION USP 1000 MG (SEFIXI 1000) (AS PER INVOICE)VLS | $88.0K | 3 |
| CEFTRIAXONE FOR INJECTION USP (SEFIXI 1000) (AS PER INVOICE) | $85.0K | 2 |
| CEFTRIAXONE FOR INJECTION USP 1000 MG (SEFIXI-1000)(AS PER INVOICE)VLS | $84.0K | 3 |
Sakar Healthcare Limited exports 56 distinct Ceftriaxone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is COMBIPACK OF CEFTRIAXONE SODIUM AND TAZO with 3 shipments worth $131.1K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Sakar Healthcare Limited Compare to Nearest Ceftriaxone Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 13 | NECTAR LIFE SCIENCES LIMITED | $4.9M | 115 | 15 | $42.6K |
| 14 | SWISS PARENTERALS LIMITED | $4.6M | 154 | 22 | $29.6K |
| 7 | SAKAR HEALTHCARE LIMITED ★ | $4.2M | 83 | 16 | $50.0K |
| 15 | VENUS REMEDIES LIMITED | $4.0M | 232 | 30 | $17.3K |
| 5 | MEDCELL PHARMA | $2.7M | 54 | 5 | $50.0K |
Sakar Healthcare Limited ranks #7 among 850 Indian Ceftriaxone exporters. Average shipment value of $50.0K compared to the market average of $115.6K. The closest competitors by value are NECTAR LIFE SCIENCES LIMITED and SWISS PARENTERALS LIMITED.
Which Indian Ports Ship Ceftriaxone Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,199 | 10.7% |
| JNPT/ NHAVA SHEVA SEA | 819 | 7.3% |
| JNPT | 675 | 6.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 547 | 4.9% |
| DELHI AIR CARGO ACC (INDEL4) | 472 | 4.2% |
| MUNDRA SEA | 460 | 4.1% |
| DELHI AIR | 457 | 4.1% |
| SAHAR AIR | 451 | 4.0% |
What Other Advanced Antibiotics Products Does Sakar Healthcare Limited Export?
Sakar Healthcare Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Sakar Healthcare Limited's Ceftriaxone Exports
Sakar Healthcare's export operations are influenced by various geopolitical factors. The ongoing Israel-Iran tensions have disrupted Red Sea shipping routes, leading to increased freight costs and potential delays. The Pharmaceuticals Export Promotion Council of India estimates that the domestic pharma industry could face losses between ₹2,500 crore and ₹5,000 crore due to these disruptions. (medicaldialogues.in) As a company with significant export activities, Sakar may need to explore alternative logistics strategies to mitigate these challenges.
In the United States, recent tariff policies have introduced uncertainties for Indian pharmaceutical exporters. While health products have been exempt from U.S. tariffs, there have been threats to impose significant increases to encourage domestic production. This situation necessitates vigilance from companies like Sakar to adapt to potential policy shifts. (lemonde.fr)
European Union regulatory changes, such as the Falsified Medicines Directive, impose stringent compliance requirements on pharmaceutical imports. Sakar's recent marketing authorizations in Europe suggest a proactive approach to meeting these standards, enhancing its competitiveness in the EU market. (prysm.fi)
Sakar Healthcare Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is crucial for Indian pharmaceutical exporters. Sakar Healthcare's successful acquisition of marketing authorizations in Europe indicates adherence to Good Manufacturing Practices (GMP) and other regulatory requirements. Additionally, the company's development of in-house APIs and obtaining Written Confirmations reflect a commitment to quality and regulatory compliance. (prysm.fi)
About Sakar Healthcare Limited
Sakar Healthcare Limited exports 6 products worth $16.0M. Beyond Ceftriaxone, top products include Cefixime, Heparin, Dexamethasone, Flucloxacillin, Diazepam. View the complete Sakar Healthcare Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ceftriaxone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ceftriaxone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Sakar Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 83 individual customs records matching Sakar Healthcare Limited exporting Ceftriaxone, covering 56 formulations to 16 countries via 38 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 162+ countries, 2,555+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ceftriaxone Export Data from Sakar Healthcare Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Sakar Healthcare Limited's Ceftriaxone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Sakar Healthcare Limited
Full Company Profile →
6 products · $16.0M total trade · 4 categories
Ceftriaxone Stats
Company Overview
Top Products by Sakar Healthcare Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Sakar Healthcare Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ceftriaxone. For current shipment-level data, contact TransData Nexus.